Denali Therapeutics’ Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected – Denali Therapeutics (NASDAQ:DNLI)
On Monday, Denali Therapeutics Inc. DNLIÂ revealed topline results from an analysis of Regimen G of the Phase 2/3…